USFDA concludes inspection at Unit-II of Aurobindo Pharma’s arm in Rajasthan

03 May 2024 Evaluate

The United States Food and Drug Administration (USFDA) has concluded the inspection at Aurobindo Pharma’s wholly owned subsidiary-- Eugia Pharma Specialities’ Unit-II, a Formulation manufacturing facility, situated at Bhiwadi, Alwar, Rajasthan. USFDA had conducted an inspection from April 25, 2024 to May 3, 2024. The inspection closed with 7 observations. The observations are procedural in nature and will be responded to within the stipulated time. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1220.20 -27.70 (-2.22%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.